Severity
Moderate
FDA Drug recall · Reported September 18, 2013
Glutathione 100 mg/mL injectable human drug is recalled due to Out Of Specification results or potential bacterial contamination and it was reported as passing by a contract labor…
Creative Compounds recalled Glutathione 100 mg/mL Injectable, 100mL Vial, Use as Directed, RX, Creative Compounds, Wi… - a moderate-severity action.
Glutathione 100 mg/mL Injectable, 100mL Vial, Use as Directed, RX, Creative Compounds, Wi… was recalled by Creative Compounds in September 18, 2013. Reason: Glutathione 100 mg/mL injectable human drug is recalled due to Out Of Specification results or potential bact…. Check the official notice for the remedy. Verify recall #D-1019-2013 with the FDA Drug before acting.
The recall
Creative Compounds issued this moderate-severity FDA Drug recall-Glutathione 100 mg/mL injectable human drug is recalled due to Out Of Specification results or potential bact….
Sourced from official FDA Drug enforcement records. Verify recall #D-1019-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1019-2013) was formally reported on September 18, 2013, with the manufacturer initiating the action on August 23, 2013. It is classified under Moderate severity (Class II), with a current status of Terminated. Creative Compounds is listed as the recalling firm, operating out of Wilsonville, OR. Federal records list the affected scope as 16 vials.
The documented reason for this recall is: Glutathione 100 mg/mL injectable human drug is recalled due to Out Of Specification results or potential bacterial contamination and it was reported as passing by a contract laboratory. Distribution data in the federal record shows the product reached: Oregon and Washington. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
16 vials
Related Recalls
6
5 from same agency
Glutathione 100 mg/mL Injectable, 100mL Vial, Use as Directed, RX, Creative Compounds, Wilsonville, OR 97070.
Glutathione 100 mg/mL injectable human drug is recalled due to Out Of Specification results or potential bacterial contamination and it was reported as passing by a contract laboratory.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1019-2013 |
| Date reported | September 18, 2013 |
| Date initiated | August 23, 2013 |
| Recalling firm | Creative Compounds |
| Firm location | Wilsonville, OR |
| Affected scope | 16 vials |
| Distribution | Oregon and Washington |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 18, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.